Effect of retinoic acid treatment on cytogenetic remission of chronic myeloid leukaemia

Acta Haematologica

Volumn 109, Issue 2, 2003, Pages 84-89

  Egyed, Miklós ^a,d   Kollár, Balázs ^a   Rumi, György ^a   Keller, Éva ^a   Vass, János ^b   Fekete, Sándorné ^c  

^a Kaposi Mor County Hospital   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c Szent Laszlo Hospital   (Hungary)

^d NONE   (Hungary)

Author keywords

All trans retinoic acid; Chronic myeloid leukaemia; EORTC LG; WHO ECOG

Indexed keywords

INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RETINOIC ACID;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; INTERPHASE; MALE; METAPHASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN INTOLERANCE; REMISSION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; INTERFERON ALFA-2A; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; TRETINOIN;

EID: 0037217360     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068494     Document Type: Article

References (26)

1. Biggs J, Szer J, Crilley P, Atkinson K, Downs K, Dodds A, Concannon AJ, Avalos B, Tutschka P, Kapoor N: Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BUCy2. Blood 1992;82:1352-1357.
2. Clift R, Appelbaum F, Thomas E: Bone marrow transplantation for chronic myelogenous leukemia. Blood 1994;83:2752-2754.
3. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA: Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994;84:2036-2043.
4. Goldman J, Szydlo R, Horowitz M, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A: Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993;82:2235-2238.
5. Gratwohl A, Hermans J, Niederwieser D: Bone marrow transplantation for chronic myeloid leukemia: Long-term results. Bone Marrow Transplant 1993;12:509-516.
6. Allen N, Richards S, Shepherd P: UK-Medical Research Council randomized, multicenter trial of interferon-alfa-nl for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 1995;345:1392-1397.
7. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Quisser W, Löffler H, Hochhaus A, Heinze B: Randomized comparison of interferon-alfa with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994;84:4064-4077.
8. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M: Review: Chronic myelogenous leukemia: A concise update. Blood 1993;82:691-703.
9. Kantarjian H, Smith T, O'Brien S, Beran M, Pierce S, Talpaz M: Prolonged survival in chronic myelogenous leukemia following cytogenetic response to alpha interferon therapy. Ann Intern Med 1995;122:254-261.
10. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM: Interferon alpha produces sustained cytogenetic responses in Philadelphia positive chronic myelogenous leukemia. Ann Intern Med 1991;114:532-538.
11. Talpaz M, Kantarjian H, McCredie K, Trujillo JM, Keating MJ, Gutterman JU: Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-1069.
12. Tura S, Baccarani M, Zuffa E, for the Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-825.
13. Bollag W: Prophylaxis of chemically induced benign and malignant epithelial tumors by Vitamin A (retinoic acid). Eur J Cancer 1972;8:689-693.
14. Bollag W, Holdener EE: Retinoids in cancer prevention and therapy, a review. Ann Oncol 1992;3:513-526.
15. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D, et al: Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multi-center randomized trial. Erupean APL 91 Group. Blood 1993;82:3241-3249.
16. Douer D, Koeffler P: Retinoic acid enhances colony stimulating factor induced growth of normal human myeloid progenitor cells in vitro. Exp Cell Res 1982;138:193-198.
17. Aglietta M, Piacibello W, Stacchini A, Sananvio F, Gavosto F: In-vitro effect of retinoic acid on normal and chronic myeloid leukemia granulopoiesis. Leukemia Res 1985;9:879-883.
18. Gallagher R, Ahearn G, Thompson D, Strack M, Paietta E, Dutcher J, Wiernik P: Retinoic acid enhanced neutrophilic differentiation of granulocyte macrophage progenitors in blastic crisis chronic myelogenous leukemia. Blood 1990;76:272.
19. Sumner AT: Chromosome banding and identification. Adsorption staining; in Gosden JR (ed): Chromosome Analysis Protocols. Methods in Molecular Biology. Totowa, Humana Press, 2000, vol 29, pp 59-81.
20. Vass JA, Kereskai L, Pajor L: Complex molecular monitoring of chronic myeloid leukemia. Orv Hetil 2000;42:2279-2285.
21. Hopman AHN, Ramaekers FCS: Processing and staining of cell and tissue material for interphase cytogenetics; in Current Protocols in Cytometry. New York, Wiley, 1999, vol 85, pp 1-22.
22. Muus P, Egyed M, Beksac M, Labar B, Indrak K, Dardenne M, Suciu S, Cevreska L, Willemze R, Stryckmans P: All-trans retinoic acid (ATRA) in addition to r-interferon-alpha in CML in first chronic phase. A feasibility study by the EORTC-LG. Blood 1999;94(suppl):1673.
23. Guilhot F, Chastang C, Michalett M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1995;337:223-229.
24. Kantarjian H, Keating M, Estey E, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M: Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alfa and low dose cytarabine. J Clin Oncol 1992;10:772-778.
25. Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Kornblau S, Keating MJ, Freireich EJ, Talpaz M: Excessive toxicity with the combination of alpha interferon (IFN alpha), low-dose cytosine arabinoside (LD-ara-C) and all-trans retinoic acid (ATRA) in patients with chronic myelogenous leukemia (CML). Blood 1998;92(suppl):4067.
26. Sokal JE, Baccarani M, Russo D, Tura S: Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25:49-61.